Embecta Corp. $EMBC Position Boosted by Krensavage Asset Management LLC

Krensavage Asset Management LLC grew its holdings in Embecta Corp. (NASDAQ:EMBC) by 54.4% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,135,340 shares of the company’s stock after purchasing an additional 400,000 shares during the period. Embecta comprises 1.4% of Krensavage Asset Management LLC’s portfolio, making the stock its 15th largest holding. Krensavage Asset Management LLC owned about 2.00% of Embecta worth $3,701,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EMBC. River Road Asset Management LLC increased its stake in shares of Embecta by 5.3% in the fourth quarter. River Road Asset Management LLC now owns 3,416,401 shares of the company’s stock worth $40,587,000 after acquiring an additional 171,194 shares during the last quarter. State Street Corp increased its position in Embecta by 1.4% in the 4th quarter. State Street Corp now owns 2,360,626 shares of the company’s stock worth $28,044,000 after purchasing an additional 31,796 shares during the last quarter. Jefferies Financial Group Inc. raised its stake in shares of Embecta by 24.9% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,354,971 shares of the company’s stock worth $27,977,000 after purchasing an additional 470,096 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Embecta by 13.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,233,869 shares of the company’s stock worth $14,658,000 after purchasing an additional 146,213 shares in the last quarter. Finally, SG Americas Securities LLC lifted its holdings in shares of Embecta by 138.4% during the 1st quarter. SG Americas Securities LLC now owns 1,038,948 shares of the company’s stock valued at $9,184,000 after buying an additional 603,106 shares during the last quarter. 93.83% of the stock is owned by hedge funds and other institutional investors.

Embecta Stock Performance

Shares of NASDAQ EMBC opened at $5.12 on Thursday. The business’s 50-day simple moving average is $4.26 and its 200-day simple moving average is $5.73. Embecta Corp. has a 52 week low of $2.77 and a 52 week high of $15.55. The firm has a market cap of $290.10 million, a price-to-earnings ratio of 3.46 and a beta of 0.86.

Embecta (NASDAQ:EMBC) last announced its earnings results on Friday, August 7th. The company reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.29. Embecta had a negative return on equity of 19.25% and a net margin of 8.59%.The firm had revenue of $271.70 million during the quarter, compared to analysts’ expectations of $254.53 million. During the same quarter in the prior year, the business earned $1.12 earnings per share. The company’s revenue was down 8.1% on a year-over-year basis. Embecta has set its FY 2026 guidance at 1.800-1.900 EPS. As a group, equities research analysts forecast that Embecta Corp. will post 1.84 earnings per share for the current year.

Embecta Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 15th. Investors of record on Thursday, August 27th will be paid a $0.01 dividend. The ex-dividend date is Thursday, August 27th. This represents a $0.04 dividend on an annualized basis and a yield of 0.8%. Embecta’s dividend payout ratio (DPR) is presently 2.70%.

Insider Activity

In other Embecta news, insider Jeffrey Z. Mann purchased 20,000 shares of the stock in a transaction dated Wednesday, August 12th. The shares were bought at an average cost of $4.99 per share, with a total value of $99,800.00. Following the completion of the transaction, the insider owned 262,915 shares in the company, valued at $1,311,945.85. This trade represents a 8.23% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Devdatt Kurdikar purchased 30,000 shares of the company’s stock in a transaction on Wednesday, August 12th. The stock was acquired at an average cost of $4.70 per share, for a total transaction of $141,000.00. Following the completion of the transaction, the chief executive officer owned 804,919 shares in the company, valued at approximately $3,783,119.30. This trade represents a 3.87% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have bought 70,000 shares of company stock worth $334,200. Insiders own 1.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on EMBC shares. Zacks Research upgraded Embecta from a “strong sell” rating to a “hold” rating in a report on Friday, July 17th. Weiss Ratings downgraded shares of Embecta from a “sell (d+)” rating to a “sell (d)” rating in a research report on Monday, August 3rd. Finally, Bank of America dropped their price target on shares of Embecta from $11.00 to $3.00 and set an “underperform” rating on the stock in a research note on Monday, May 18th. Three analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and an average target price of $11.00.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.